1
|
Guignard S, Saifeddine M, Mihara K, Motahhary M, Savignac M, Guiraud L, Sagnat D, Sebbag M, Khou S, Rolland C, Edir A, Bournet B, Buscail L, Buscail E, Alric L, Camare C, Ambli M, Vergnolle N, Hollenberg MD, Deraison C, Bonnart C. Chymotrypsin activity signals to intestinal epithelium by protease-activated receptor-dependent mechanisms. Br J Pharmacol 2024. [PMID: 38637276 DOI: 10.1111/bph.16341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 01/04/2024] [Accepted: 01/30/2024] [Indexed: 04/20/2024] Open
Abstract
BACKGROUND AND PURPOSE Chymotrypsin is a pancreatic protease secreted into the lumen of the small intestine to digest food proteins. We hypothesized that chymotrypsin activity may be found close to epithelial cells and that chymotrypsin signals to them via protease-activated receptors (PARs). We deciphered molecular pharmacological mechanisms and gene expression regulation for chymotrypsin signalling in intestinal epithelial cells. EXPERIMENTAL APPROACH The presence and activity of chymotrypsin were evaluated by Western blot and enzymatic activity tests in the luminal and mucosal compartments of murine and human gut samples. The ability of chymotrypsin to cleave the extracellular domain of PAR1 or PAR2 was assessed using cell lines expressing N-terminally tagged receptors. The cleavage site of chymotrypsin on PAR1 and PAR2 was determined by HPLC-MS analysis. The chymotrypsin signalling mechanism was investigated in CMT93 intestinal epithelial cells by calcium mobilization assays and Western blot analyses of (ERK1/2) phosphorylation. The transcriptional consequences of chymotrypsin signalling were analysed on colonic organoids. KEY RESULTS We found that chymotrypsin was present and active in the vicinity of the colonic epithelium. Molecular pharmacological studies have shown that chymotrypsin cleaves both PAR1 and PAR2 receptors. Chymotrypsin activated calcium and ERK1/2 signalling pathways through PAR2, and this pathway promoted interleukin-10 (IL-10) up-regulation in colonic organoids. In contrast, chymotrypsin disarmed PAR1, preventing further activation by its canonical agonist, thrombin. CONCLUSION AND IMPLICATIONS Our results highlight the ability of chymotrypsin to signal to intestinal epithelial cells via PARs, which may have important physiological consequences in gut homeostasis.
Collapse
Affiliation(s)
- Simon Guignard
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Mahmoud Saifeddine
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Koichiro Mihara
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Majid Motahhary
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Magali Savignac
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-Centre National de la Recherche Scientifique UMR5051, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Laura Guiraud
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - David Sagnat
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Mireille Sebbag
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Sokchea Khou
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Corinne Rolland
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Anissa Edir
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Barbara Bournet
- Department of Gastroenterology, Toulouse University Hospital, Toulouse, France
| | - Louis Buscail
- Department of Gastroenterology, Toulouse University Hospital, Toulouse, France
| | - Etienne Buscail
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
- Department of Digestive Surgery, Toulouse University Hospital, Toulouse, France
| | - Laurent Alric
- Department of Internal Medicine and Digestive Diseases, Rangueil, Toulouse III University Hospital, University of Toulouse, Toulouse, France
| | - Caroline Camare
- Department of Clinical Biochemistry, Toulouse University Hospital, Toulouse, France
- University of Toulouse, UMR1297, INSERM/Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Mouna Ambli
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Nathalie Vergnolle
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Morley D Hollenberg
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Céline Deraison
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| | - Chrystelle Bonnart
- IRSD, University of Toulouse, INSERM, INRAE, ENVT, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France
| |
Collapse
|
2
|
Mihara K, Kanemoto I, Sato K, Yasuhira Y, Watanabe I, Misumi K. Corrigendum to 'Echocardiographic evaluation of deformity and enlargement of the canine mitral valve annulus associated with myxomatous degenerative mitral valve disease' [J Vet Cardiol (2021) 37, 8-17]. J Vet Cardiol 2023; 45:1-2. [PMID: 36512887 DOI: 10.1016/j.jvc.2022.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- K Mihara
- Joint Graduate School of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima, 8900065, Japan; Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan.
| | - I Kanemoto
- Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan
| | - K Sato
- Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan
| | - Y Yasuhira
- Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan
| | - I Watanabe
- Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan
| | - K Misumi
- Joint Graduate School of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima, 8900065, Japan
| |
Collapse
|
3
|
Mihara K, Saifeddine M, Hollenberg MD. Metformin down‐regulates TGF beta signal transduction and production of PAR2 N‐terminus cleaving protease activity in an NR4a1 dependent manner in a PC3 prostate cancer cell line. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r2300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Koichiro Mihara
- Physiology and PharmacologyUniversity of Calgary Cumming School of MedicineCalgaryAB
| | - Mahmoud Saifeddine
- Physiology and PharmacologyUniversity of Calgary Cumming School of MedicineCalgaryAB
| | - Morley D. Hollenberg
- Physiololgy & Pharmacology, and MedicineUniversity of Calgary Cumming School of MedicineCalgaryAB
- Physiology & Pharmacology, and MedicineSnyder Institute for Chronic DiseasesCalgaryAB
| |
Collapse
|
4
|
Williams D, Mahmoud M, Liu R, Andueza A, Kumar S, Kang DW, Zhang J, Tamargo I, Villa-Roel N, Baek KI, Lee H, An Y, Zhang L, Tate EW, Bagchi P, Pohl J, Mosnier LO, Diamandis EP, Mihara K, Hollenberg MD, Dai Z, Jo H. Stable flow-induced expression of KLK10 inhibits endothelial inflammation and atherosclerosis. eLife 2022; 11:e72579. [PMID: 35014606 PMCID: PMC8806187 DOI: 10.7554/elife.72579] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 01/08/2022] [Indexed: 12/15/2022] Open
Abstract
Atherosclerosis preferentially occurs in arterial regions exposed to disturbed blood flow (d-flow), while regions exposed to stable flow (s-flow) are protected. The proatherogenic and atheroprotective effects of d-flow and s-flow are mediated in part by the global changes in endothelial cell (EC) gene expression, which regulates endothelial dysfunction, inflammation, and atherosclerosis. Previously, we identified kallikrein-related peptidase 10 (Klk10, a secreted serine protease) as a flow-sensitive gene in mouse arterial ECs, but its role in endothelial biology and atherosclerosis was unknown. Here, we show that KLK10 is upregulated under s-flow conditions and downregulated under d-flow conditions using in vivo mouse models and in vitro studies with cultured ECs. Single-cell RNA sequencing (scRNAseq) and scATAC sequencing (scATACseq) study using the partial carotid ligation mouse model showed flow-regulated Klk10 expression at the epigenomic and transcription levels. Functionally, KLK10 protected against d-flow-induced permeability dysfunction and inflammation in human artery ECs, as determined by NFκB activation, expression of vascular cell adhesion molecule 1 and intracellular adhesion molecule 1, and monocyte adhesion. Furthermore, treatment of mice in vivo with rKLK10 decreased arterial endothelial inflammation in d-flow regions. Additionally, rKLK10 injection or ultrasound-mediated transfection of Klk10-expressing plasmids inhibited atherosclerosis in Apoe-/- mice. Moreover, KLK10 expression was significantly reduced in human coronary arteries with advanced atherosclerotic plaques compared to those with less severe plaques. KLK10 is a flow-sensitive endothelial protein that serves as an anti-inflammatory, barrier-protective, and anti-atherogenic factor.
Collapse
Affiliation(s)
- Darian Williams
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
- Molecular and Systems Pharmacology Program, Emory UniversityAtlantaUnited States
| | - Marwa Mahmoud
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
| | - Renfa Liu
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
- Department of Biomedical Engineering, Peking UniversityBeijingChina
| | - Aitor Andueza
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
| | - Sandeep Kumar
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
| | - Dong-Won Kang
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
| | - Jiahui Zhang
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
| | - Ian Tamargo
- Molecular and Systems Pharmacology Program, Emory UniversityAtlantaUnited States
| | - Nicolas Villa-Roel
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
| | - Kyung-In Baek
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
| | | | | | - Leran Zhang
- Department of Chemistry, Imperial College LondonLondonUnited Kingdom
| | - Edward W Tate
- Department of Chemistry, Imperial College LondonLondonUnited Kingdom
| | - Pritha Bagchi
- Emory Integrated Proteomics Core, Emory UniversityAtlantaUnited States
| | - Jan Pohl
- Biotechnology Core Facility Branch, Centers for Disease Control and PreventionAtlantaUnited States
| | - Laurent O Mosnier
- Department of Molecular Medicine, Scripps Research InstituteSan DiegoUnited States
| | | | - Koichiro Mihara
- Department of Physiology and Pharmacology, University of CalgaryCalgaryCanada
| | - Morley D Hollenberg
- Department of Physiology and Pharmacology, University of CalgaryCalgaryCanada
| | - Zhifei Dai
- Department of Biomedical Engineering, Peking UniversityBeijingChina
| | - Hanjoong Jo
- Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of TechnologyAtlantaUnited States
- Molecular and Systems Pharmacology Program, Emory UniversityAtlantaUnited States
- Department of Medicine, Emory UniversityAtlantaUnited States
| |
Collapse
|
5
|
Brownsey DK, Rowley BC, Gorobets E, Mihara K, Maity R, Papatzimas JW, Gelfand BS, Hollenberg MD, Bahlis NJ, Derksen DJ. Identification of ligand linkage vectors for the development of p300/CBP degraders. RSC Med Chem 2022; 13:726-730. [PMID: 35814928 PMCID: PMC9215131 DOI: 10.1039/d1md00070e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Accepted: 04/12/2022] [Indexed: 01/10/2023] Open
Abstract
To develop new degrader molecules from an existing protein ligand a linkage vector must be identified and then joined with a suitable E3 ligase without disrupting binding to the respective...
Collapse
Affiliation(s)
- Duncan K Brownsey
- Department of Chemistry, University of Calgary 2500 University Drive NW T2N 1N4 Calgary Alberta Canada
- Arnie Charbonneau Cancer Institute, University of Calgary 3280 Hospital Drive NW T2N 4Z6 Calgary Alberta Canada
| | - Ben C Rowley
- Department of Chemistry, University of Calgary 2500 University Drive NW T2N 1N4 Calgary Alberta Canada
- Arnie Charbonneau Cancer Institute, University of Calgary 3280 Hospital Drive NW T2N 4Z6 Calgary Alberta Canada
| | - Evgueni Gorobets
- Department of Chemistry, University of Calgary 2500 University Drive NW T2N 1N4 Calgary Alberta Canada
- Arnie Charbonneau Cancer Institute, University of Calgary 3280 Hospital Drive NW T2N 4Z6 Calgary Alberta Canada
| | - Koichiro Mihara
- Department of Physiology and Pharmacology, University of Calgary 3330 Hospital Drive NW T2N 4N1 Calgary Canada
| | - Ranjan Maity
- Arnie Charbonneau Cancer Institute, University of Calgary 3280 Hospital Drive NW T2N 4Z6 Calgary Alberta Canada
| | - James W Papatzimas
- Department of Chemistry, University of Calgary 2500 University Drive NW T2N 1N4 Calgary Alberta Canada
- Arnie Charbonneau Cancer Institute, University of Calgary 3280 Hospital Drive NW T2N 4Z6 Calgary Alberta Canada
| | - Benjamin S Gelfand
- Department of Chemistry, University of Calgary 2500 University Drive NW T2N 1N4 Calgary Alberta Canada
| | - Morley D Hollenberg
- Department of Physiology and Pharmacology, University of Calgary 3330 Hospital Drive NW T2N 4N1 Calgary Canada
| | - Nizar J Bahlis
- Arnie Charbonneau Cancer Institute, University of Calgary 3280 Hospital Drive NW T2N 4Z6 Calgary Alberta Canada
| | - Darren J Derksen
- Department of Chemistry, University of Calgary 2500 University Drive NW T2N 1N4 Calgary Alberta Canada
- Arnie Charbonneau Cancer Institute, University of Calgary 3280 Hospital Drive NW T2N 4Z6 Calgary Alberta Canada
| |
Collapse
|
6
|
Fekete E, Allain T, Amat CB, Mihara K, Saifeddine M, Hollenberg MD, Chadee K, Buret AG. Giardia duodenalis cysteine proteases cleave proteinase-activated receptor-2 to regulate intestinal goblet cell mucin gene expression. Int J Parasitol 2022; 52:285-292. [DOI: 10.1016/j.ijpara.2021.11.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 11/10/2021] [Accepted: 11/11/2021] [Indexed: 12/17/2022]
|
7
|
Abji F, Rasti M, Gómez-Aristizábal A, Muytjens C, Saifeddine M, Mihara K, Motahhari M, Gandhi R, Viswanathan S, Hollenberg MD, Oikonomopoulou K, Chandran V. Corrigendum: Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis. Front Immunol 2021; 12:814072. [PMID: 34975926 PMCID: PMC8715513 DOI: 10.3389/fimmu.2021.814072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Accepted: 11/18/2021] [Indexed: 11/14/2022] Open
Affiliation(s)
- Fatima Abji
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
| | - Mozhgan Rasti
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
| | | | - Carla Muytjens
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
| | - Mahmoud Saifeddine
- Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Koichiro Mihara
- Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Majid Motahhari
- Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Rajiv Gandhi
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
- Division of Orthopaedic Surgery, Department of Surgery, Toronto Western Hospital, Toronto, ON, Canada
| | - Sowmya Viswanathan
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
- Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada
- Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Morley D. Hollenberg
- Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Katerina Oikonomopoulou
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
- *Correspondence: Katerina Oikonomopoulou, ; Vinod Chandran,
| | - Vinod Chandran
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
- Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- Department of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada
- *Correspondence: Katerina Oikonomopoulou, ; Vinod Chandran,
| |
Collapse
|
8
|
Mihara K, Kanemoto I, Sato K, Yasuhira Y, Watanabe I, Misumi K. Echocardiographic evaluation of deformity and enlargement of the canine mitral valve annulus associated with myxomatous degenerative mitral valve disease. J Vet Cardiol 2021; 37:8-17. [PMID: 34507141 DOI: 10.1016/j.jvc.2021.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 07/24/2021] [Accepted: 08/09/2021] [Indexed: 12/15/2022]
Abstract
INTRODUCTION/OBJECTIVES Quantitative evaluation of the morphology of the mitral valve annulus (MVA) in dogs with myxomatous mitral valve disease (MMVD) may improve the techniques of mitral valve plasty. This study aimed to compare the MVA morphology on echocardiography in normal dogs and dogs with MMVD and to compare the echocardiographic and intraoperative measurements of the MVA in dogs with MMVD. ANIMALS, MATERIALS AND METHODS The study population comprised 59 healthy dogs (control group) and 371 dogs with MMVD (MMVD group). The anterior-posterior diameter and transversal diameter (TD) of the MVA and the aortic annulus diameter were measured by echocardiography to calculate the mitral valve flattening ratio, mitral annulus area (MAA), mitral annulus circumference (MAC), contraction ratio of the MAA and aortic annulus area. In the MMVD group, the mitral annulus diameter (MAD) was macroscopically measured during mitral valve plasty. Areas and lengths were divided by the body surface area (BSA) and √BSA, respectively, for comparative analyses. RESULTS The systolic and diastolic anterior-posterior diameter/√BSA, transversal diameter/√BSA, MAA/BSA converted to a natural logarithm (Ln(MAA/BSA)), and MAC/√BSA was significantly higher in the MMVD group than the control group, whereas flattening ratio values and contraction ratio of the MAA was significantly lower. Neither the aortic annulus diameter /√BSA nor the Ln(aortic annulus area/BSA) significantly differed between groups. In the MMVD group, diastolic MAC/√BSA and MAA/BSA correlated significantly with the MAD/√BSA. CONCLUSIONS The MVA is larger and rounder in dogs with MMVD than controls. Two-dimensional echocardiographic measures of MAA and MAC correlate well with intraoperative measures of MAD.
Collapse
Affiliation(s)
- K Mihara
- Joint Graduate School of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima, 8900065, Japan; Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan.
| | - I Kanemoto
- Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan
| | - K Sato
- Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan
| | - Y Yasuhira
- Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan
| | - I Watanabe
- Chayagasaka Animal Hospital, 1-1-5 Shin-nishi, Chikusa-ku, Nagoya, 4640003, Japan
| | - K Misumi
- Joint Graduate School of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima, 8900065, Japan
| |
Collapse
|
9
|
Venu VKP, Saifeddine M, Mihara K, Faiza M, Gorobets E, Flewelling AJ, Derksen DJ, Hirota SA, Marei I, Al-Majid D, Motahhary M, Ding H, Triggle CR, Hollenberg MD. Metformin Prevents Hyperglycemia-Associated, Oxidative Stress-Induced Vascular Endothelial Dysfunction: Essential Role for the Orphan Nuclear Receptor Human Nuclear Receptor 4A1 (Nur77). Mol Pharmacol 2021; 100:428-455. [PMID: 34452975 DOI: 10.1124/molpharm.120.000148] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Accepted: 08/17/2021] [Indexed: 01/22/2023] Open
Abstract
Vascular pathology is increased in diabetes because of reactive-oxygen-species (ROS)-induced endothelial cell damage. We found that in vitro and in a streptozotocin diabetes model in vivo, metformin at diabetes-therapeutic concentrations (1-50 µM) protects tissue-intact and cultured vascular endothelial cells from hyperglycemia/ROS-induced dysfunction typified by reduced agonist-stimulated endothelium-dependent, nitric oxide-mediated vasorelaxation in response to muscarinic or proteinase-activated-receptor 2 agonists. Metformin not only attenuated hyperglycemia-induced ROS production in aorta-derived endothelial cell cultures but also prevented hyperglycemia-induced endothelial mitochondrial dysfunction (reduced oxygen consumption rate). These endothelium-protective effects of metformin were absent in orphan-nuclear-receptor Nr4a1-null murine aorta tissues in accord with our observing a direct metformin-Nr4a1 interaction. Using in silico modeling of metformin-NR4A1 interactions, Nr4a1-mutagenesis, and a transfected human embryonic kidney 293T cell functional assay for metformin-activated Nr4a1, we identified two Nr4a1 prolines, P505/P549 (mouse sequences corresponding to human P501/P546), as key residues for enabling metformin to affect mitochondrial function. Our data indicate a critical role for Nr4a1 in metformin's endothelial-protective effects observed at micromolar concentrations, which activate AMPKinase but do not affect mitochondrial complex-I or complex-III oxygen consumption rates, as does 0.5 mM metformin. Thus, therapeutic metformin concentrations requiring the expression of Nr4a1 protect the vasculature from hyperglycemia-induced dysfunction in addition to metformin's action to enhance insulin action in patients with diabetes. SIGNIFICANCE STATEMENT: Metformin improves diabetic vasodilator function, having cardioprotective effects beyond glycemic control, but its mechanism to do so is unknown. We found that metformin at therapeutic concentrations (1-50µM) prevents hyperglycemia-induced endothelial dysfunction by attenuating reactive oxygen species-induced damage, whereas high metformin (>250 µM) impairs vascular function. However, metformin's action requires the expression of the orphan nuclear receptor NR4A1/Nur77. Our data reveal a novel mechanism whereby metformin preserves diabetic vascular endothelial function, with implications for developing new metformin-related therapeutic agents.
Collapse
Affiliation(s)
- Vivek Krishna Pulakazhi Venu
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Mahmoud Saifeddine
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Koichiro Mihara
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Muniba Faiza
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Evgueni Gorobets
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Andrew J Flewelling
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Darren J Derksen
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Simon A Hirota
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Isra Marei
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Dana Al-Majid
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Majid Motahhary
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Hong Ding
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Chris R Triggle
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| | - Morley D Hollenberg
- Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology (V.K.P.V, M.S., K.M., M.M., S.A.H., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary AB, Canada; Alberta Children's Hospital Research Institute and Department of Chemistry, University of Calgary AB, Canada (E.G., A.J.F., D.D.); Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar, Al-Rayyan, Doha, Qatar (I. M., D. A-M., H.D., C.R.T.) and Bioinformatics (M.F.), Jamia Millia Islamia (Central University), Jaima Nagar, Okhla New Delhi, India
| |
Collapse
|
10
|
Fekete E, Amat C, Allain T, Mihara K, Hollenberg M, Chadee K, Buret A. Structural and Chemical Alterations to the Intestinal Mucus Barrier during
Giardia duodenalis
Infection. FASEB J 2021. [DOI: 10.1096/fasebj.2021.35.s1.02078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
11
|
Renouf M, Mihara K, Saifeddine M, Hollenberg M. Microglial cell secretion of serpin‐like trypsin‐inhibitory activity: potential regulation of proteinase‐activated receptor‐2 (PAR2)‐mediated inflammatory signalling. FASEB J 2021. [DOI: 10.1096/fasebj.2021.35.s1.05081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
12
|
Hollenberg M, Mihara K. Proteolytic Signal Crosstalk in the Prostate Cancer Microenvironment: PC3 Cell Metalloproteinases and Autocrine‐paracrine‐fibroblast Regulation of Proteinase‐activated Receptors (PARs). FASEB J 2021. [DOI: 10.1096/fasebj.2021.35.s1.05158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
13
|
Abji F, Rasti M, Gómez-Aristizábal A, Muytjens C, Saifeddine M, Mihara K, Motahhari M, Gandhi R, Viswanathan S, Hollenberg MD, Oikonomopoulou K, Chandran V. Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis. Front Immunol 2021; 11:629726. [PMID: 33763056 PMCID: PMC7982406 DOI: 10.3389/fimmu.2020.629726] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Accepted: 12/29/2020] [Indexed: 11/29/2022] Open
Abstract
Objective Multiple proteinases are present in the synovial fluid (SF) of an arthritic joint. We aimed to identify inflammatory cell populations present in psoriatic arthritis (PsA) SF compared to osteoarthritis (OA) and rheumatoid arthritis (RA), identify their proteinase-activated receptor 2 (PAR2) signaling function and characterize potentially active SF serine proteinases that may be PAR2 activators. Methods Flow cytometry was used to characterize SF cells from PsA, RA, OA patients; PsA SF cells were further characterized by single cell 3’-RNA-sequencing. Active serine proteinases were identified through cleavage of fluorogenic trypsin- and chymotrypsin-like substrates, activity-based probe analysis and proteomics. Fluo-4 AM was used to monitor intracellular calcium cell signaling. Cytokine expression was evaluated using a multiplex Luminex panel. Results PsA SF cells were dominated by monocytes/macrophages, which consisted of three populations representing classical, non-classical and intermediate cells. The classical monocytes/macrophages were reduced in PsA compared to OA/RA, whilst the intermediate population was increased. PAR2 was elevated in OA vs. PsA/RA SF monocytes/macrophages, particularly in the intermediate population. PAR2 expression and signaling in primary PsA monocytes/macrophages significantly impacted the production of monocyte chemoattractant protein-1 (MCP-1). Trypsin-like serine proteinase activity was elevated in PsA and RA SF compared to OA, while chymotrypsin-like activity was elevated in RA compared to PsA. Tryptase-6 was identified as an active serine proteinase in SF that could trigger calcium signaling partially via PAR2. Conclusion PAR2 and its activating proteinases, including tryptase-6, can be important mediators of inflammation in PsA. Components within this proteinase-receptor axis may represent novel therapeutic targets.
Collapse
Affiliation(s)
- Fatima Abji
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
| | - Mozhgan Rasti
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
| | | | - Carla Muytjens
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
| | - Mahmoud Saifeddine
- Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Koichiro Mihara
- Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Majid Motahhari
- Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Rajiv Gandhi
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.,Division of Orthopaedic Surgery, Department of Surgery, Toronto Western Hospital, Toronto, ON, Canada
| | - Sowmya Viswanathan
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.,Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada.,Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Morley D Hollenberg
- Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.,Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Katerina Oikonomopoulou
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
| | - Vinod Chandran
- Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.,Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.,Institute of Medical Science, University of Toronto, Toronto, ON, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.,Department of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada
| |
Collapse
|
14
|
Fekete E, Amat CB, Allain T, Hollenberg M, Mihara K, Chadee K, Buret A. A50 MODULATION OF GOBLET CELL ACTIVITY DURING GIARDIA DUODENALIS INFECTION: A ROLE FOR PAR2. J Can Assoc Gastroenterol 2021. [DOI: 10.1093/jcag/gwab002.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Giardia duodenalis has been shown to alter the structure of the intestinal mucus layers during infection via obscure mechanisms. We hypothesize that goblet cell activity may be disrupted in part due to proteolytic activation of protease-activated receptor 2 (PAR2) by Giardia proteases, resulting in disruption of mucus production and secretion by intestinal goblet cells.
Aims
Characterize alterations in goblet cell activity during Giardia infection, focusing on the roles of Giardia protease activity and PAR2.
Methods
Chinese hamster ovary cells transfected with nano-luciferase tagged PAR2 were incubated with Giardia NF or GSM trophozoites. Cleavage within the activation domain results in release of enzymes into the supernatant. Luminescence in the supernatant was measured as an indication of PAR cleavage by Giardia.
LS174T, a human colonic mucus-producing cell line, was infected with Giardia trophozoites (isolates NF, WB, S2, and GSM). Prior to infection, trophozoites were treated with E64, a broad-spectrum cysteine protease inhibitor, and LS174T were treated with a PAR2 antagonist, a calcium chelator, or an ERK1/2 inhibitor. Quantitative PCR (qPCR) was performed for the MUC2 mucin gene.
Wild-type (WT) and PAR2 knockout (KO) mice were infected with Giardia. Colonic mucus was stained using fluorescein-coupled wheat-germ agglutinin (WGA), and qPCR was performed for Muc2 and Muc5ac.
Results
Giardia trophozoites cleaved PAR2 within the N-terminal activation domain in a cysteine protease-dependent manner. Cleavage was isolate dependent, with isolates that show higher protease activity cleaving at a higher rate.
High protease activity Giardia isolates increased MUC2 gene expression in LS714T. This increase was attenuated by inhibition of Giardia cysteine protease activity, and by antagonism of PAR2, inhibition of calcium release, or inhibition of ERK1/2 activity in LS174T cells.
Both Muc2 and Muc5ac expression were upregulated in the colons of WT mice in response to Giardia infection, while in the jejunum Muc2 expression decreased and Muc5ac expression increased. In KO, no changes in gene expression were seen in the colon in response to Giardia infection, while in the jejunum, Muc2 expression was unchanged and Muc5ac expression decreased. Both WT infected and KO noninfected mice showed thinning of the colonic mucus layer compared to WT controls. There was some recovery in thickness in KO infected mice.
Conclusions
PAR2 plays a significant role in the regulation of mucin gene expression in mice and in a human colonic cell line. Results suggest that Giardia cysteine proteases cleave and activate PAR2, leading to calcium release and activation of the MAPK pathway in goblet cells, ultimately leading to altered mucin gene expression. Findings identify a novel regulatory pathway for mucus production by intestinal goblet cells.
Funding Agencies
CAG, CCC
Collapse
Affiliation(s)
- E Fekete
- Biological Sciences, University of Calgary, Calgary, AB, Canada
| | - C B Amat
- Biological Sciences, University of Calgary, Calgary, AB, Canada
| | - T Allain
- University of Calgary, Calgary, AB, Canada
| | - M Hollenberg
- Biological Sciences, University of Calgary, Calgary, AB, Canada
| | - K Mihara
- Biological Sciences, University of Calgary, Calgary, AB, Canada
| | - K Chadee
- Biological Sciences, University of Calgary, Calgary, AB, Canada
| | - A Buret
- Biological Sciences, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
15
|
de Lima SG, Eskaros A, Mihara K, Saifeddine M, Zijlstra A, Hyndman ME, Hollenberg MD. Organotypic & in vitro monolayer modeling of urothelial carcinoma gives different cellular responses to proteinase activated receptor (PAR) agonism/antagonism. Urol Oncol 2020. [DOI: 10.1016/j.urolonc.2020.10.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Kondo T, Tanaka M, Yamataka K, Kikuchi Y, Mihara K, Shito M. Laparoscopic reversal of Hartmann's procedure using the reverse transrectal stapling technique. Tech Coloproctol 2020; 24:1309-1310. [PMID: 32683597 DOI: 10.1007/s10151-020-02302-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Accepted: 07/12/2020] [Indexed: 10/23/2022]
Affiliation(s)
- T Kondo
- Department of Surgery, Kawasaki Municipal Hospital, 12-1 Shinkawadori Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan.
| | - M Tanaka
- Department of Surgery, Kawasaki Municipal Hospital, 12-1 Shinkawadori Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan. .,Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
| | - K Yamataka
- Department of Surgery, Kawasaki Municipal Hospital, 12-1 Shinkawadori Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan
| | - Y Kikuchi
- Department of Surgery, Kawasaki Municipal Hospital, 12-1 Shinkawadori Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan
| | - K Mihara
- Department of Surgery, Kawasaki Municipal Hospital, 12-1 Shinkawadori Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan
| | - M Shito
- Department of Surgery, Kawasaki Municipal Hospital, 12-1 Shinkawadori Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan
| |
Collapse
|
17
|
Petrushina I, Litvinenko VN, Jing Y, Ma J, Pinayev I, Shih K, Wang G, Wu YH, Altinbas Z, Brutus JC, Belomestnykh S, Di Lieto A, Inacker P, Jamilkowski J, Mahler G, Mapes M, Miller T, Narayan G, Paniccia M, Roser T, Severino F, Skaritka J, Smart L, Smith K, Soria V, Than Y, Tuozzolo J, Wang E, Xiao B, Xin T, Ben-Zvi I, Boulware C, Grimm T, Mihara K, Kayran D, Rao T. High-Brightness Continuous-Wave Electron Beams from Superconducting Radio-Frequency Photoemission Gun. Phys Rev Lett 2020; 124:244801. [PMID: 32639812 DOI: 10.1103/physrevlett.124.244801] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Accepted: 05/29/2020] [Indexed: 06/11/2023]
Abstract
Continuous-wave photoinjectors operating at high accelerating gradients promise to revolutionize many areas of science and applications. They can establish the basis for a new generation of monochromatic x-ray free electron lasers, high-brightness hadron beams, or a new generation of microchip production. In this Letter we report on the record-performing superconducting rf electron gun with CsK_{2}Sb photocathode. The gun is generating high charge electron bunches (up to 10 nC/bunch) and low transverse emittances, while operating for months with a single photocathode. This achievement opens a new era in generating high-power beams with a very high average brightness.
Collapse
Affiliation(s)
- I Petrushina
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - V N Litvinenko
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y Jing
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Ma
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I Pinayev
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Shih
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
| | - G Wang
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y H Wu
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
| | - Z Altinbas
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J C Brutus
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Belomestnykh
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Di Lieto
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Inacker
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Jamilkowski
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Mahler
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Mapes
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Miller
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Narayan
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Paniccia
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Roser
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - F Severino
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Skaritka
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Smart
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Smith
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - V Soria
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y Than
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Tuozzolo
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E Wang
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B Xiao
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Xin
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I Ben-Zvi
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Boulware
- Niowave Inc., Lansing, Michigan 48906, USA
| | - T Grimm
- Niowave Inc., Lansing, Michigan 48906, USA
| | - K Mihara
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
| | - D Kayran
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Rao
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| |
Collapse
|
18
|
Fekete ER, Amat C, Allain T, Mihara K, Hollenberg M, Chadee K, Buret A. Alterations to Mucus Production and Secretion during
Giardia
Infection Involve
Giardia
Protease Activity and PAR2 Activation. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.02365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
19
|
Venu VKP, Saifeddine M, Mihara K, Kamal B, Lantela D, Hollenberg MD. NON‐PSYCHOACTIVE CANNABINOIDS (CBD/CBG) ACT VIA CANNABINOID CB2/CB1 RECEPTORS TO REGULATE INTESTINAL MYOFIBROBLAST METABOLIC ACTIVITY AND TO INHIBIT FORSKOLIN‐MEDIATED ELEVATION OF CYCLIC‐AMP. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.02225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
20
|
Otterbein H, Mihara K, Hollenberg MD, Lehnert H, Witte D, Ungefroren H. RAC1B Suppresses TGF-β-Dependent Chemokinesis and Growth Inhibition through an Autoregulatory Feed-Forward Loop Involving PAR2 and ALK5. Cancers (Basel) 2019; 11:cancers11081211. [PMID: 31434318 PMCID: PMC6721813 DOI: 10.3390/cancers11081211] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 08/13/2019] [Accepted: 08/16/2019] [Indexed: 02/06/2023] Open
Abstract
The small GTPase RAC1B functions as a powerful inhibitor of transforming growth factor (TGF)-β1-induced epithelial-mesenchymal transition, cell motility, and growth arrest in pancreatic epithelial cells. Previous work has shown that RAC1B downregulates the TGF-β type I receptor ALK5, but the molecular details of this process have remained unclear. Here, we hypothesized that RAC1B-mediated suppression of activin receptor-like kinase 5 (ALK5) involves proteinase-activated receptor 2 (PAR2), a G protein-coupled receptor encoded by F2RL1 that is crucial for sustaining ALK5 expression. We found in pancreatic carcinoma Panc1 cells that PAR2 is upregulated by TGF-β1 in an ALK5-dependent manner and that siRNA-mediated knockdown of RAC1B increased both basal and TGF-β1-induced expression of PAR2. Further, the simultaneous knockdown of PAR2 and RAC1B rescued Panc1 cells from a RAC1B knockdown-induced increase in ALK5 abundance and the ALK5-mediated increase in TGF-β1-induced migratory activity. Conversely, Panc1 cells with stable ectopic expression of RAC1B displayed reduced ALK5 expression, an impaired upregulation of PAR2, and a reduced migratory responsiveness to TGF-β1 stimulation. However, these effects could be reversed by ectopic overexpression of PAR2. Moreover, the knockdown of PAR2 alone in Panc1 cells and HaCaT keratinocytes phenocopied RAC1B's ability to suppress ALK5 abundance and TGF-β1-induced chemokinesis and growth inhibition. Lastly, we found that the RAC1B knockdown-induced increase in TGF-β1-induced PAR2 mRNA expression was sensitive to pharmacological inhibition of MEK-ERK signaling. Our data show that in pancreatic and skin epithelial cells, downregulation of ALK5 activity by RAC1B is secondary to suppression of F2RL1/PAR2 expression. Since F2RL1 itself is a TGF-β target gene and its upregulation by TGF-β1 is mediated by ALK5 and MEK-ERK signaling, we suggest the existence of a feed-forward signaling loop involving ALK5 and PAR2 that is efficiently suppressed by RAC1B to restrict TGF-β-driven cell motility and growth inhibition.
Collapse
Affiliation(s)
- Hannah Otterbein
- First Department of Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Koichiro Mihara
- Departments of Physiology and Pharmacology and Medicine, Inflammation Research Network, Snyder Institute for Chronic Diseases, University of Calgary, Cumming School of Medicine, Calgary, AB T2N 4N1, Canada
| | - Morley D Hollenberg
- Departments of Physiology and Pharmacology and Medicine, Inflammation Research Network, Snyder Institute for Chronic Diseases, University of Calgary, Cumming School of Medicine, Calgary, AB T2N 4N1, Canada
| | - Hendrik Lehnert
- First Department of Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - David Witte
- First Department of Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany.
| | - Hendrik Ungefroren
- First Department of Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany.
- Clinic for General Surgery, Visceral, Thoracic, Transplantation and Pediatric Surgery, University Hospital Schleswig-Holstein, Campus Kiel, D-24105 Kiel, Germany.
| |
Collapse
|
21
|
Pulakazhi Venu VK, Saifeddine M, Mihara K, Tsai YC, Nieves K, Alston L, Mani S, McCoy KD, Hollenberg MD, Hirota SA. The pregnane X receptor and its microbiota-derived ligand indole 3-propionic acid regulate endothelium-dependent vasodilation. Am J Physiol Endocrinol Metab 2019; 317:E350-E361. [PMID: 31211619 PMCID: PMC6732469 DOI: 10.1152/ajpendo.00572.2018] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
We proposed that circulating metabolites generated by the intestinal microbiota can affect vascular function. One such metabolite, indole 3-propionic acid (IPA), can activate the pregnane X receptor(PXR), a xenobiotic-activated nuclear receptor present in many tissues, including the vascular endothelium. We hypothesized that IPA could regulate vascular function by modulating PXR activity. To test this, Pxr+/+ mice were administered broad-spectrum antibiotics for 2 wk with IPA supplementation. Vascular function was evaluated by bioassay using aorta and pulmonary artery ring tissue from antibiotic-treated Pxr+/+ and Pxr-/-mice, supplemented with IPA, and using aorta tissue maintained in organ culture for 24 h in the presence of IPA. Endothelium-dependent, nitric oxide(NO)-mediated muscarinic and proteinase-activated receptor 2(PAR2)-stimulated vasodilation was assessed. Endothelial nitric oxide synthase (eNOS) abundance was evaluated in intact tissue or in aorta-derived endothelial cell cultures from Pxr+/+ and Pxr-/- mice, and vascular Pxr levels were assessed in tissues obtained from Pxr+/+ mice treated with antibiotics and supplemented with IPA. Antibiotic-treated Pxr+/+ mice exhibited enhanced agonist-induced endothelium-dependent vasodilation, which was phenocopied by tissues from either Pxr-/- or germ-free mice. IPA exposure reduced the vasodilatory responses in isolated and cultured vessels. No effects of IPA were observed for tissues obtained from Pxr-/- mice. Serum nitrate levels were increased in antibiotic-treated Pxr+/+and Pxr-/- mice. eNOS abundance was increased in aorta tissues and cultured endothelium from Pxr-/- mice. PXR stimulation reduced eNOS expression in cultured endothelial cells from Pxr+/+ but not Pxr-/- mice. The microbial metabolite IPA, via the PXR, plays a key role in regulating endothelial function. Furthermore, antibiotic treatment changes PXR-mediated vascular endothelial responsiveness by upregulating eNOS.
Collapse
Affiliation(s)
- Vivek Krishna Pulakazhi Venu
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Mahmoud Saifeddine
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Koichiro Mihara
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Yi-Cheng Tsai
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Kristoff Nieves
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Laurie Alston
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Sridhar Mani
- Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
| | - Kathy D McCoy
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Morley D Hollenberg
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Simon A Hirota
- Inflammation Research Network-Snyder Institute for Chronic Disease, Calgary, Alberta, Canada
- Department of Physiology and Pharmacology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| |
Collapse
|
22
|
Eftekhari R, de Lima SG, Liu Y, Mihara K, Saifeddine M, Noorbakhsh F, Scarisbrick IA, Hollenberg MD. Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation. Biol Chem 2019; 399:1023-1039. [PMID: 29924723 DOI: 10.1515/hsz-2018-0001] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2018] [Accepted: 06/08/2018] [Indexed: 12/17/2022]
Abstract
We propose that in the microenvironment of inflammatory tissues, including tumours, extracellular proteinases can modulate cell signalling in part by regulating proteinase-activated receptors (PARs). We have been exploring this mechanism in a variety of inflammation and tumour-related settings that include tumour-derived cultured cells from prostate and bladder cancer, as well as immune inflammatory cells that are involved in the pathology of inflammatory diseases including multiple sclerosis. Our work showed that proteinase signalling via the PARs affects prostate and bladder cancer-derived tumour cell behaviour and can regulate calcium signalling in human T-cell and macrophage-related inflammatory cells as well as in murine splenocytes. Further, we found that the tumour-derived prostate cancer cells and immune-related cells (Jurkat, THP1, mouse splenocytes) can produce PAR-regulating proteinases (including kallikreins: kallikrein-related peptidases), that can control tissue function by both a paracrine and autocrine mechanism. We suggest that this PAR-driven signalling process involving secreted microenvironment proteinases can play a key role in cancer and inflammatory diseases including multiple sclerosis.
Collapse
Affiliation(s)
- Rahil Eftekhari
- Inflammation Research Network-Snyder Institute for Chronic Disease, Departments of Physiology and Pharmacology and Medicine, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada.,Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1416753955, Iran
| | - Stacy G de Lima
- Inflammation Research Network-Snyder Institute for Chronic Disease, Departments of Physiology and Pharmacology and Medicine, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada
| | - Yu Liu
- Inflammation Research Network-Snyder Institute for Chronic Disease, Departments of Physiology and Pharmacology and Medicine, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada
| | - Koichiro Mihara
- Inflammation Research Network-Snyder Institute for Chronic Disease, Departments of Physiology and Pharmacology and Medicine, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada
| | - Mahmoud Saifeddine
- Inflammation Research Network-Snyder Institute for Chronic Disease, Departments of Physiology and Pharmacology and Medicine, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada
| | - Farshid Noorbakhsh
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1416753955, Iran
| | - Isobel A Scarisbrick
- Department of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, MN 55905, USA
| | - Morley D Hollenberg
- Inflammation Research Network-Snyder Institute for Chronic Disease, Departments of Physiology and Pharmacology and Medicine, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada
| |
Collapse
|
23
|
Fekete E, Amat C, Allain T, Mihara K, Hollenberg M, Chadee K, Buret A. Giardia
‐Induced Alterations to Intestinal Mucus Production Involve Protease‐Activated Receptor‐2‐Mediated Activation of MAPK and Calcium Release. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.38.10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Elena Fekete
- Biological SciencesUniversity of CalgaryCalgaryABCanada
| | | | | | - Koichiro Mihara
- Physiology and PharmacologyUniversity of CalgaryCalgaryABCanada
| | | | | | - Andre Buret
- Biological SciencesUniversity of CalgaryCalgaryABCanada
| |
Collapse
|
24
|
Carr BJ, Mihara K, Ramachandran R, Saifeddine M, Nathanson NM, Stell WK, Hollenberg MD. Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro. Invest Ophthalmol Vis Sci 2019; 59:2778-2791. [PMID: 29860464 DOI: 10.1167/iovs.17-22562] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Purpose Myopia is a refractive disorder that degrades vision. It can be treated with atropine, a muscarinic acetylcholine receptor (mAChR) antagonist, but the mechanism is unknown. Atropine may block α-adrenoceptors at concentrations ≥0.1 mM, and another potent myopia-inhibiting ligand, mamba toxin-3 (MT3), binds equally well to human mAChR M4 and α1A- and α2A-adrenoceptors. We hypothesized that mAChR antagonists could inhibit myopia via α2A-adrenoceptors, rather than mAChR M4. Methods Human mAChR M4 (M4), chicken mAChR M4 (cM4), or human α2A-adrenergic receptor (hADRA2A) clones were cotransfected with CRE/promoter-luciferase (CRE-Luc; agonist-induced luminescence) and Renilla luciferase (RLuc; normalizing control) into human cells. Inhibition of normalized agonist-induced luminescence by antagonists (ATR: atropine; MT3; HIM: himbacine; PRZ: pirenzepine; TRP: tropicamide; OXY: oxyphenonium; QNB: 3-quinuclidinyl benzilate; DIC: dicyclomine; MEP: mepenzolate) was measured using the Dual-Glo Luciferase Assay System. Results Relative inhibitory potencies of mAChR antagonists at mAChR M4/cM4, from most to least potent, were QNB > OXY ≥ ATR > MEP > HIM > DIC > PRZ > TRP. MT3 was 56× less potent at cM4 than at M4. Relative potencies of mAChR antagonists at hADRA2A, from most to least potent, were MT3 > HIM > ATR > OXY > PRZ > TRP > QNB > MEP; DIC did not antagonize. Conclusions Muscarinic antagonists block hADRA2A signaling at concentrations comparable to those used to inhibit chick myopia (≥0.1 mM) in vivo. Relative potencies at hADRA2A, but not M4/cM4, correlate with reported abilities to inhibit chick form-deprivation myopia. mAChR antagonists might inhibit myopia via α2-adrenoceptors, instead of through the mAChR M4/cM4 receptor subtype.
Collapse
Affiliation(s)
- Brittany J Carr
- Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Inflammation Research Network-Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Neuroscience, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Koichiro Mihara
- Inflammation Research Network-Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Rithwik Ramachandran
- Inflammation Research Network-Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Physiology and Pharmacology, Western University, London, Ontario, Canada
| | - Mahmoud Saifeddine
- Inflammation Research Network-Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Neil M Nathanson
- Department of Pharmacology, University of Washington, Seattle, Washington, United States
| | - William K Stell
- Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Morley D Hollenberg
- Inflammation Research Network-Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
25
|
Sachan V, Lodge R, Mihara K, Hamelin J, Power C, Gelman BB, Hollenberg MD, Cohen ÉA, Seidah NG. HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin. Cell Death Differ 2019; 26:1942-1954. [PMID: 30683917 DOI: 10.1038/s41418-018-0264-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 12/12/2018] [Accepted: 12/17/2018] [Indexed: 02/08/2023] Open
Abstract
HIV-associated neurocognitive disorders (HAND) is a syndrome defined by neurocognitive deficits that are driven by viral neurotoxins, cytokines, free radicals, and proteases expressed in the brain. This neurological disease has also been linked to activation of Protease-Activated Receptors 1 and 2 (PAR1,2). These receptors are highly expressed in the central nervous system and are upregulated in HAND. Secretory basic-amino-acid-specific Proprotein Convertases (PCs), which cleave precursor proteins at basic residues, are also induced in HAND. They are vital for many biological processes including HIV-1 entry into cells. The cytoprotective role of Furin, PC5, and PACE4 has been linked to the presence of a potential PC-cleavage site R41XXXXR46↓ in PAR1. Furthermore, Furin binds PAR1 and both are trapped in the trans-Golgi-network (TGN) as inactive proteins, likely due to the intermediary trafficking role of phospho-Furin acidic cluster sorting protein 1 (PACS1). Nothing is known about PAR2 and its possible recognition by PCs at its putative R31XXXXR36↓ processing site. The present study implicates PACS1 in the retrograde trafficking of PAR1 to the TGN and demonstrates that the cytosolic extreme C-terminal tail of PAR1 contains an acidic phosphorylatable PACS1-sensitive domain. We further show the requirement of Asn47 in PAR1 for its Furin-dependent TGN localization. Our data revealed that Furin is the only convertase that efficiently cleaves PAR2 at Arg36↓. N-glycosylation of PAR2 at Asn30 reduces the efficacy, but enhances selectivity of the Furin cleavage. Finally, in co-cultures comprised of human neuroblastoma SK-N-SH cells (stably expressing PAR1/2 and/or Furin) and HIV-1-infected primary macrophages, we demonstrate that the expression of Furin enhances neuronal cell viability in the context of PAR1- or PAR2-induced neuronal cytotoxicity. The present study provides insights into early stages of HIV-1 induced neuronal injury and the protective role of Furin in neurons co-expressing PAR1 and/or PAR2, as observed in HAND.
Collapse
Affiliation(s)
- Vatsal Sachan
- Laboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (affiliated to the University of Montreal), 110 Pine Ave West, Montreal, QC, H2W1R7, Canada
| | - Robert Lodge
- Laboratory of Human Retrovirology, Montreal Clinical Research Institute (affiliated to the University of Montreal), 110 Pine Ave West, Montreal, QC, H2W1R7, Canada
| | - Koichiro Mihara
- Inflammation Research Network-Snyder Institute for Chronic Diseases, Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.,Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, AB, T2N4N1, Canada
| | - Josée Hamelin
- Laboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (affiliated to the University of Montreal), 110 Pine Ave West, Montreal, QC, H2W1R7, Canada
| | - Christopher Power
- Department of Medicine, University of Alberta, Edmonton, AB, T6G2S2, Canada
| | - Benjamin B Gelman
- Department of Pathology, University of Texas Medical Branch Houston, Galveston, 77555, TX, USA
| | - Morley D Hollenberg
- Inflammation Research Network-Snyder Institute for Chronic Diseases, Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.,Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, AB, T2N4N1, Canada
| | - Éric A Cohen
- Laboratory of Human Retrovirology, Montreal Clinical Research Institute (affiliated to the University of Montreal), 110 Pine Ave West, Montreal, QC, H2W1R7, Canada
| | - Nabil G Seidah
- Laboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (affiliated to the University of Montreal), 110 Pine Ave West, Montreal, QC, H2W1R7, Canada.
| |
Collapse
|
26
|
El-Daly M, Pulakazhi Venu VK, Saifeddine M, Mihara K, Kang S, Fedak PW, Alston LA, Hirota SA, Ding H, Triggle CR, Hollenberg MD. Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. Vascul Pharmacol 2018; 109:56-71. [DOI: 10.1016/j.vph.2018.06.006] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Revised: 05/05/2018] [Accepted: 06/09/2018] [Indexed: 01/16/2023]
|
27
|
Pulakazhi Venu VK, Saifeddine M, Mihara K, El-Daly M, Belke D, Dean JLE, O'Brien ER, Hirota SA, Hollenberg MD. Heat shock protein-27 and sex-selective regulation of muscarinic and proteinase-activated receptor 2-mediated vasodilatation: differential sensitivity to endothelial NOS inhibition. Br J Pharmacol 2018. [PMID: 29532457 DOI: 10.1111/bph.14200] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND AND PURPOSE Previously, we demonstrated that exogenous heat shock protein 27 (HSP27/gene, HSPB1) treatment of human endothelial progenitor cells (EPCs) increases the synthesis and secretion of VEGF, improves EPC-migration/re-endothelialization and decreases neo-intima formation, suggesting a role for HSPB1 in regulating EPC function. We hypothesized that HSPB1 also affects mature endothelial cells (ECs) to alter EC-mediated vasoreactivity in vivo. Our work focused on endothelial NOS (eNOS)/NO-dependent relaxation induced by ACh and the coagulation pathway-activated receptor, proteinase-activated receptor 2 (PAR2). EXPERIMENTAL APPROACH Aorta rings from male and female wild-type, HSPB1-null and HSPB1 overexpressing (HSPB1o/e) mice were contracted with phenylephrine, and NOS-dependent relaxation responses to ACh and PAR2 agonist, 2-furoyl-LIGRLO-NH2 , were measured without and with L-NAME and ODQ, either alone or in combination to block NO synthesis/action. Tissues from female HSPB1-null mice were treated in vitro with recombinant HSP27 and then used for bioassay as above. Furthermore, oestrogen-specific effects were evaluated using a bioassay of aorta isolated from ovariectomized mice. KEY RESULTS Relative to males, HSPB1-null female mice exhibited an increased L-NAME-resistant relaxation induced by activation of either PAR2 or muscarinic ACh receptors that was blocked in the concurrent presence of both L-NAME and ODQ. mRNAs (qPCR) for eNOS and ODQ-sensitive guanylyl-cyclase were increased in females versus males. Treatment of isolated aorta tissue with HSPB1 improved tissue responsiveness in the presence of L-NAME. Ovariectomy did not affect NO sensitivity, supporting an oestrogen-independent role for HSPB1. CONCLUSIONS AND IMPLICATIONS HSPB1 can regulate intact vascular endothelial function to affect NO-mediated vascular relaxation, especially in females.
Collapse
Affiliation(s)
- Vivek Krishna Pulakazhi Venu
- Department of Physiology and Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.,Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Mahmoud Saifeddine
- Department of Physiology and Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Koichiro Mihara
- Department of Physiology and Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Mahmoud El-Daly
- Department of Physiology and Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.,Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt
| | - Darrell Belke
- Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Jonathan L E Dean
- Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | - Edward R O'Brien
- Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Simon A Hirota
- Department of Physiology and Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Morley D Hollenberg
- Department of Physiology and Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.,Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| |
Collapse
|
28
|
Ungefroren H, Witte D, Mihara K, Rauch BH, Henklein P, Jöhren O, Bonni S, Settmacher U, Lehnert H, Hollenberg MD, Kaufmann R, Gieseler F. Transforming Growth Factor-β1/Activin Receptor-like Kinase 5-Mediated Cell Migration is Dependent on the Protein Proteinase-Activated Receptor 2 but not on Proteinase-Activated Receptor 2-Stimulated Gq-Calcium Signaling. Mol Pharmacol 2017; 92:519-532. [DOI: 10.1124/mol.117.109017] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 08/07/2017] [Indexed: 01/01/2023] Open
|
29
|
Polley DJ, Mihara K, Ramachandran R, Vliagoftis H, Renaux B, Saifeddine M, Daines MO, Boitano S, Hollenberg MD. Cockroach allergen serine proteinases: Isolation, sequencing and signalling via proteinase-activated receptor-2. Clin Exp Allergy 2017; 47:946-960. [PMID: 28317204 DOI: 10.1111/cea.12921] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Revised: 01/18/2017] [Accepted: 01/19/2017] [Indexed: 02/01/2023]
Abstract
BACKGROUND Allergy to the German cockroach (Blattella germanica) is a significant asthma risk factor for inner-city communities. Cockroach, like other allergens, contains trypsin-like enzyme activity that contributes to allergenicity and airway inflammation by activating proteinase-activated receptors (PARs). To date, the enzymes responsible for the proteolytic activity of German cockroach allergen have not been characterized. OBJECTIVES We aimed to identify, isolate and characterize the trypsin-like proteinases in German cockroach allergen extracts used for clinical skin tests. For each enzyme, we sought to determine (1) its substrate and inhibitor enzyme kinetics (Km and IC50), (2) its amino acid sequence and (3) its ability to activate calcium signalling and/or ERK1/2 phosphorylation via PAR2. METHODS Using a trypsin-specific activity-based probe, we detected three distinct enzymes that were isolated using ion-exchange chromatography. Each enzyme was sequenced by mass spectometery (deconvoluted with an expressed sequence tag library), evaluated kinetically for its substrate/inhibitor profile and assessed for its ability to activate PAR2 signalling. FINDINGS Each of the three serine proteinase activity-based probe-labelled enzymes isolated was biochemically distinct, with different enzyme kinetic profiles and primary amino acid sequences. The three enzymes showed a 57%-71% sequence identity with a proteinase previously cloned from the American cockroach (Per a 10). Each enzyme was found to activate both Ca++ and MAPK signalling via PAR2. CONCLUSIONS AND RELEVANCE We have identified three different serine proteinases from the German cockroach that may, via PAR2 activation, play different roles for allergen sensitization in vivo and may represent attractive therapeutic targets for asthma.
Collapse
Affiliation(s)
- D J Polley
- Department of Physiology & Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - K Mihara
- Department of Physiology & Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - R Ramachandran
- Department of Physiology & Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - H Vliagoftis
- Pulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - B Renaux
- Department of Physiology & Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - M Saifeddine
- Department of Physiology & Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - M O Daines
- Asthma & Airway Disease Research Center, University of Arizona, Tucson, AZ, USA
| | - S Boitano
- Asthma & Airway Disease Research Center, University of Arizona, Tucson, AZ, USA
| | - M D Hollenberg
- Department of Physiology & Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Disease, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.,Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| |
Collapse
|
30
|
Ramachandran R, Mihara K, Thibeault P, Vanderboor CM, Petri B, Saifeddine M, Bouvier M, Hollenberg MD. Targeting a Proteinase-Activated Receptor 4 (PAR4) Carboxyl Terminal Motif to Regulate Platelet Function. Mol Pharmacol 2017; 91:287-295. [PMID: 28126849 DOI: 10.1124/mol.116.106526] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 01/18/2017] [Indexed: 12/22/2022] Open
Abstract
Thrombin initiates human platelet aggregation by coordinately activating proteinase-activated receptors (PARs) 1 and 4. However, targeting PAR1 with an orthosteric-tethered ligand binding-site antagonist results in bleeding, possibly owing to the important role of PAR1 activation on cells other than platelets. Because of its more restricted tissue expression profile, we have therefore turned to PAR4 as an antiplatelet target. We have identified an intracellular PAR4 C-terminal motif that regulates calcium signaling and β-arrestin interactions. By disrupting this PAR4 calcium/β-arrestin signaling process with a novel cell-penetrating peptide, we were able to inhibit both thrombin-triggered platelet aggregation in vitro and clot consolidation in vivo. We suggest that targeting PAR4 represents an attractive alternative to blocking PAR1 for antiplatelet therapy in humans.
Collapse
Affiliation(s)
- Rithwik Ramachandran
- Snyder Institute for Chronic Diseases and Department of Physiology and Pharmacology (R.R., K.M., M.S., M.D.H.), Mouse Phenomics Resource Laboratory, Snyder Institute for Chronic Diseases and Department of Microbiology, Immunology, and Infectious Diseases (B.P.), and Department of Medicine (M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.R., P.T., C.M.V.); and IRIC-Université de Montréal, Montréal, Québec, Canada (M.B.)
| | - Koichiro Mihara
- Snyder Institute for Chronic Diseases and Department of Physiology and Pharmacology (R.R., K.M., M.S., M.D.H.), Mouse Phenomics Resource Laboratory, Snyder Institute for Chronic Diseases and Department of Microbiology, Immunology, and Infectious Diseases (B.P.), and Department of Medicine (M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.R., P.T., C.M.V.); and IRIC-Université de Montréal, Montréal, Québec, Canada (M.B.)
| | - Pierre Thibeault
- Snyder Institute for Chronic Diseases and Department of Physiology and Pharmacology (R.R., K.M., M.S., M.D.H.), Mouse Phenomics Resource Laboratory, Snyder Institute for Chronic Diseases and Department of Microbiology, Immunology, and Infectious Diseases (B.P.), and Department of Medicine (M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.R., P.T., C.M.V.); and IRIC-Université de Montréal, Montréal, Québec, Canada (M.B.)
| | - Christina M Vanderboor
- Snyder Institute for Chronic Diseases and Department of Physiology and Pharmacology (R.R., K.M., M.S., M.D.H.), Mouse Phenomics Resource Laboratory, Snyder Institute for Chronic Diseases and Department of Microbiology, Immunology, and Infectious Diseases (B.P.), and Department of Medicine (M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.R., P.T., C.M.V.); and IRIC-Université de Montréal, Montréal, Québec, Canada (M.B.)
| | - Björn Petri
- Snyder Institute for Chronic Diseases and Department of Physiology and Pharmacology (R.R., K.M., M.S., M.D.H.), Mouse Phenomics Resource Laboratory, Snyder Institute for Chronic Diseases and Department of Microbiology, Immunology, and Infectious Diseases (B.P.), and Department of Medicine (M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.R., P.T., C.M.V.); and IRIC-Université de Montréal, Montréal, Québec, Canada (M.B.)
| | - Mahmoud Saifeddine
- Snyder Institute for Chronic Diseases and Department of Physiology and Pharmacology (R.R., K.M., M.S., M.D.H.), Mouse Phenomics Resource Laboratory, Snyder Institute for Chronic Diseases and Department of Microbiology, Immunology, and Infectious Diseases (B.P.), and Department of Medicine (M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.R., P.T., C.M.V.); and IRIC-Université de Montréal, Montréal, Québec, Canada (M.B.)
| | - Michel Bouvier
- Snyder Institute for Chronic Diseases and Department of Physiology and Pharmacology (R.R., K.M., M.S., M.D.H.), Mouse Phenomics Resource Laboratory, Snyder Institute for Chronic Diseases and Department of Microbiology, Immunology, and Infectious Diseases (B.P.), and Department of Medicine (M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.R., P.T., C.M.V.); and IRIC-Université de Montréal, Montréal, Québec, Canada (M.B.)
| | - Morley D Hollenberg
- Snyder Institute for Chronic Diseases and Department of Physiology and Pharmacology (R.R., K.M., M.S., M.D.H.), Mouse Phenomics Resource Laboratory, Snyder Institute for Chronic Diseases and Department of Microbiology, Immunology, and Infectious Diseases (B.P.), and Department of Medicine (M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.R., P.T., C.M.V.); and IRIC-Université de Montréal, Montréal, Québec, Canada (M.B.)
| |
Collapse
|
31
|
Mihara K, Ramachandran R, Saifeddine M, Hansen KK, Renaux B, Polley D, Gibson S, Vanderboor C, Hollenberg MD. Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2: Another Target for Thrombin Signaling. Mol Pharmacol 2016; 89:606-14. [PMID: 26957205 DOI: 10.1124/mol.115.102723] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2015] [Accepted: 03/03/2016] [Indexed: 01/30/2023] Open
Abstract
Thrombin is known to signal to cells by cleaving/activating a G-protein-coupled family of proteinase-activated receptors (PARs). The signaling mechanism involves the proteolytic unmasking of an N-terminal receptor sequence that acts as a tethered receptor-activating ligand. To date, the recognized targets of thrombin cleavage and activation for signaling are PAR1 and PAR4, in which thrombin cleaves at a conserved target arginine to reveal a tethered ligand. PAR2, which like PAR1 is also cleaved at an N-terminal arginine to unmask its tethered ligand, is generally regarded as a target for trypsin but not for thrombin signaling. We now show that thrombin, at concentrations that can be achieved at sites of acute injury or in a tumor microenvironment, can directly activate PAR2 vasorelaxation and signaling, stimulating calcium and mitogen-activated protein kinase responses along with triggeringβ-arrestin recruitment. Thus, PAR2 can be added alongside PAR1 and PAR4 to the targets, whereby thrombin can affect tissue function.
Collapse
Affiliation(s)
- Koichiro Mihara
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| | - Rithwik Ramachandran
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| | - Mahmoud Saifeddine
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| | - Kristina K Hansen
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| | - Bernard Renaux
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| | - Danny Polley
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| | - Stacy Gibson
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| | - Christina Vanderboor
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| | - Morley D Hollenberg
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology (K.M., R.R., M.S., K.K.H., B.R., D.P., S.G., M.D.H.), and Department of Medicine (M.D.H.), University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada; and Department of Physiology and Pharmacology, Western University, London, Ontario, Canada (C.V., R.R.)
| |
Collapse
|
32
|
Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, Takizawa J, Mitani K, Igarashi T, Sakai K, Miyazaki K, Mihara K, Ohmachi K, Nakamura N, Takasaki H, Kiyoi H, Nakamura S, Kinoshita T, Ogura M. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J 2015; 5:e372. [PMID: 26636287 PMCID: PMC4735068 DOI: 10.1038/bcj.2015.101] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Affiliation(s)
- T Aoki
- Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.,Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Shimada
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - R Suzuki
- Cancer Center, Shimane University Hospital, Izumo, Japan
| | - K Izutsu
- Department of Hematology, Toranomon Hospital, Tokyo, Japan
| | - A Tomita
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Maeda
- Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan
| | - J Takizawa
- Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan
| | - K Mitani
- Department of Hematology and Oncology, Dokkyo Medical University School of Medicine, Tochigi, Japan
| | - T Igarashi
- Department of Hematology and Oncology, Gunma Cancer Center, Oota, Japan
| | - K Sakai
- Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan.,Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Miyazaki
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
| | - K Mihara
- Department of Hematology, Hiroshima University Hospital, Hiroshima, Japan
| | - K Ohmachi
- Department of Hematology, Tokai University, Isehara, Japan
| | - N Nakamura
- Department of Pathology, Tokai University, Isehara, Japan
| | - H Takasaki
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - H Kiyoi
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Nakamura
- Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan
| | - T Kinoshita
- Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan
| | - M Ogura
- Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.,Department of Hematology, Tokai Central Hospital, Kakamigahara, Japan
| |
Collapse
|
33
|
HOLLENBERG M, Mihara K, Liu Y, Ramachandran R. Identification of a Prostate Cancer Cell Proteinase Activated Receptor/MMP Signaling Axis. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.629.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Morley HOLLENBERG
- Snyder Institute for Chronic DiseasesDepartment of Physiology & Pharmacology University of Calgary Cumming School of MedicineCalgaryAlbertaCanada
| | - Koichiro Mihara
- Snyder Institute for Chronic DiseasesDepartment of Physiology & Pharmacology University of Calgary Cumming School of MedicineCalgaryAlbertaCanada
| | - Yu Liu
- Snyder Institute for Chronic DiseasesDepartment of Physiology & Pharmacology University of Calgary Cumming School of MedicineCalgaryAlbertaCanada
| | - Rithwik Ramachandran
- Snyder Institute for Chronic DiseasesDepartment of Physiology & Pharmacology University of Calgary Cumming School of MedicineCalgaryAlbertaCanada
| |
Collapse
|
34
|
Saifeddine M, El-Daly M, Mihara K, Bunnett NW, McIntyre P, Altier C, Hollenberg MD, Ramachandran R. GPCR-mediated EGF receptor transactivation regulates TRPV4 action in the vasculature. Br J Pharmacol 2015; 172:2493-506. [PMID: 25572823 DOI: 10.1111/bph.13072] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Revised: 11/18/2014] [Accepted: 12/28/2014] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND AND PURPOSE Transient receptor potential vanilloid-4 (TRPV4) is a calcium-permeant ion channel that is known to affect vascular function. The ability of TRPV4 to cause a vasoconstriction in blood vessels has not yet been mechanistically examined. Further in neuronal cells, TRPV4 signalling can be potentiated by GPCR activation. Thus, we studied the mechanisms underlying the vascular contractile action of TRPV4 and the GPCR-mediated potentiation of such vasoconstriction, both of which are as yet unappreciated aspects of TRPV4 function. EXPERIMENTAL APPROACH The mechanisms of TRPV4-dependent regulation of vascular tone in isolated mouse aortae were studied using wire myography. TRPV4-dependent calcium signalling and prostanoid production was studied in cultured human umbilical vein endothelial cells (HUVECs). KEY RESULTS In addition to the well-documented vasorelaxation response triggered by TRPV4 activation, we report here a TRPV4-triggered vasoconstriction in the mouse aorta that involves a COX-generated Tx receptor (TP) agonist that acts in a MAPK and Src kinase signalling dependent manner. This constriction is potentiated by activation of the GPCRs for angiotensin (AT1 receptors) or proteinases (PAR1 and PAR2) via transactivation of the EGF receptor and a process involving PKC. TRPV4-dependent vascular contraction can be blocked by COX inhibitors or with TP antagonists. Further, TRPV4 activation in HUVECs stimulated Tx release as detected by an elisa. CONCLUSION AND IMPLICATIONS We conclude that the GPCR potentiation of TRPV4 action and TRPV4-dependent Tx receptor activation are important regulators of vascular function and could be therapeutically targeted in vascular diseases.
Collapse
Affiliation(s)
- Mahmoud Saifeddine
- Department of Physiology and Pharmacology, Inflammation Research Network and Snyder Institute for Chronic Disease, University of Calgary, Calgary, AB, Canada
| | | | | | | | | | | | | | | |
Collapse
|
35
|
El-Daly M, Saifeddine M, Mihara K, Ramachandran R, Triggle CR, Hollenberg MD. Proteinase-activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways. Br J Pharmacol 2014; 171:2413-25. [PMID: 24506284 DOI: 10.1111/bph.12593] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Revised: 12/23/2013] [Accepted: 01/17/2014] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND AND PURPOSE Because angiotensin-II-mediated porcine coronary artery (PCA) vasoconstriction is blocked by protein tyrosine kinase (PYK) inhibitors, we hypothesized that proteinase-activated receptors (PARs), known to regulate vascular tension, like angiotensin-II, would also cause PCA contractions via PYK-dependent signalling pathways. EXPERIMENTAL APPROACH Contractions of intact and endothelium-free isolated PCA rings, stimulated by PAR1 /PAR2 -activating peptides, angiotensin-II, PGF2α , EGF, PDGF and KCl, were monitored with/without multiple signalling pathway inhibitors, including AG-tyrphostins AG18 (non-specific PYKs), AG1478 (EGF-receptor kinase), AG1296 (PDGF receptor kinase), PP1 (Src kinase), U0126 and PD98059 (MEK/MAPKinase kinase), indomethacin/SC-560/NS-398 (COX-1/2) and L-NAME (NOS). KEY RESULTS AG18 inhibited the contractions induced by all the agonists except KCl, whereas U0126 attenuated contractions induced by PAR1 /PAR2 agonists, EGF and angiotensin-II, but not by PGF2α , the COX-produced metabolites of arachidonate and KCl. PP1 only affected the responses to PAR1 /PAR2 -activating peptides and angiotensin-II. The EGF-kinase inhibitor, AG1478, attenuated contractions initiated by the PARs (PAR2 >> PAR1 ) and EGF itself, but not by angiotensin-II, PGF2α or KCl. COX-1/2 inhibitors blocked the contractions induced by all the agonists, except KCl and PGF2α . CONCLUSION AND IMPLICATIONS PAR1/2 -mediated contractions of the PCA are dependent on Src and MAPKinase and, in part, involve EGF-receptor-kinase transactivation and the generation of a COX-derived contractile agonist. However, the PYK signalling pathways used by PARs are distinct from each other and from those triggered by angiotensin-II and EGF. These signalling pathways may be therapeutic targets for managing coagulation-proteinase-induced coronary vasospasm.
Collapse
Affiliation(s)
- Mahmoud El-Daly
- Libin Cardiovascular Institute of Alberta and the Snyder Institute for Chronic Diseases, Calgary, AB, Canada; Department of Physiology and Pharmacology, The University of Calgary Faculty of Medicine, Calgary, AB, Canada
| | | | | | | | | | | |
Collapse
|
36
|
Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, Ramachandran R. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. Br J Pharmacol 2014; 171:1180-94. [PMID: 24354792 DOI: 10.1111/bph.12544] [Citation(s) in RCA: 130] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2013] [Revised: 11/13/2013] [Accepted: 11/26/2013] [Indexed: 12/13/2022] Open
Abstract
Although it has been known since the 1960s that trypsin and chymotrypsin can mimic hormone action in tissues, it took until the 1990s to discover that serine proteinases can regulate cells by cleaving and activating a unique four-member family of GPCRs known as proteinase-activated receptors (PARs). PAR activation involves the proteolytic exposure of its N-terminal receptor sequence that folds back to function as a 'tethered' receptor-activating ligand (TL). A key N-terminal arginine in each of PARs 1 to 4 has been singled out as a target for cleavage by thrombin (PARs 1, 3 and 4), trypsin (PARs 2 and 4) or other proteases to unmask the TL that activates signalling via Gq , Gi or G12 /13 . Similarly, synthetic receptor-activating peptides, corresponding to the exposed 'TL sequences' (e.g. SFLLRN-, for PAR1 or SLIGRL- for PAR2) can, like proteinase activation, also drive signalling via Gq , Gi and G12 /13 , without requiring receptor cleavage. Recent data show, however, that distinct proteinase-revealed 'non-canonical' PAR tethered-ligand sequences and PAR-activating agonist and antagonist peptide analogues can induce 'biased' PAR signalling, for example, via G12 /13 -MAPKinase instead of Gq -calcium. This overview summarizes implications of this 'biased' signalling by PAR agonists and antagonists for the recognized roles the PARs play in inflammatory settings.
Collapse
Affiliation(s)
- M D Hollenberg
- Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada; Faculty of Medicine, Department of Medicine, University of Calgary, Calgary, AB, Canada
| | | | | | | | | | | | | |
Collapse
|
37
|
Iablokov V, Hirota CL, Peplowski MA, Ramachandran R, Mihara K, Hollenberg MD, MacNaughton WK. Proteinase-activated receptor 2 (PAR2) decreases apoptosis in colonic epithelial cells. J Biol Chem 2014; 289:34366-77. [PMID: 25331954 DOI: 10.1074/jbc.m114.610485] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Mucosal biopsies from inflamed colon of inflammatory bowel disease patients exhibit elevated epithelial apoptosis compared with those from healthy individuals, disrupting mucosal homeostasis and perpetuating disease. Therapies that decrease intestinal epithelial apoptosis may, therefore, ameliorate inflammatory bowel disease, but treatments that specifically target apoptotic pathways are lacking. Proteinase-activated receptor-2 (PAR2), a G protein-coupled receptor activated by trypsin-like serine proteinases, is expressed on intestinal epithelial cells and stimulates mitogenic pathways upon activation. We sought to determine whether PAR2 activation and signaling could rescue colonic epithelial (HT-29) cells from apoptosis induced by proapoptotic cytokines that are increased during inflammatory bowel disease. The PAR2 agonists 2-furoyl-LIGRLO (2f-LI), SLIGKV and trypsin all significantly reduced cleavage of caspase-3, -8, and -9, poly(ADP-ribose) polymerase, and the externalization of phosphatidylserine after treatment of cells with IFN-γ and TNF-α. Knockdown of PAR2 with siRNA eliminated the anti-apoptotic effect of 2f-LI and increased the sensitivity of HT-29 cells to cytokine-induced apoptosis. Concurrent inhibition of both MEK1/2 and PI3K was necessary to inhibit PAR2-induced survival. 2f-LI was found to increase phosphorylation and inactivation of pro-apoptotic BAD at Ser(112) and Ser(136) by MEK1/2 and PI3K-dependent signaling, respectively. PAR2 activation also increased the expression of anti-apoptotic MCL-1. Simultaneous knockdown of both BAD and MCL-1 had minimal effects on PAR2-induced survival, whereas single knockdown had no effect. We conclude that PAR2 activation reduces cytokine-induced epithelial apoptosis via concurrent stimulation of MEK1/2 and PI3K but little involvement of MCL-1 and BAD. Our findings represent a novel mechanism whereby serine proteinases facilitate epithelial cell survival and may be important in the context of colonic healing.
Collapse
Affiliation(s)
- Vadim Iablokov
- From the Department of Physiology and Pharmacology, the Inflammation Research Network, and the Snyder Institute for Chronic Diseases, University of Calgary, Alberta T2N 4N1, Canada
| | - Christina L Hirota
- From the Department of Physiology and Pharmacology, the Inflammation Research Network, and the Snyder Institute for Chronic Diseases, University of Calgary, Alberta T2N 4N1, Canada
| | - Michael A Peplowski
- From the Department of Physiology and Pharmacology, the Inflammation Research Network, and the Snyder Institute for Chronic Diseases, University of Calgary, Alberta T2N 4N1, Canada
| | - Rithwik Ramachandran
- From the Department of Physiology and Pharmacology, the Inflammation Research Network, and the Snyder Institute for Chronic Diseases, University of Calgary, Alberta T2N 4N1, Canada
| | - Koichiro Mihara
- From the Department of Physiology and Pharmacology, the Inflammation Research Network, and the Snyder Institute for Chronic Diseases, University of Calgary, Alberta T2N 4N1, Canada
| | - Morley D Hollenberg
- From the Department of Physiology and Pharmacology, the Inflammation Research Network, and the Snyder Institute for Chronic Diseases, University of Calgary, Alberta T2N 4N1, Canada
| | - Wallace K MacNaughton
- From the Department of Physiology and Pharmacology, the Inflammation Research Network, and the Snyder Institute for Chronic Diseases, University of Calgary, Alberta T2N 4N1, Canada
| |
Collapse
|
38
|
Nemoto K, Mihara K, Nakamura A, Nagai G, Kagawa S, Suzuki T, Kondo T. Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients. Pharmacopsychiatry 2014; 47:101-4. [PMID: 24764200 DOI: 10.1055/s-0034-1372644] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
INTRODUCTION The effects of escitalopram (10 mg/d) coadministration on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, were studied in 13 Japanese psychiatric patients and compared with those of paroxetine (10 mg/d) coadministration. METHODS The patients had received 6-24 mg/d of aripiprazole for at least 2 weeks. Patients were randomly allocated to one of 2 treatment sequences: paroxetine-escitalopram (n=6) or escitalopram-paroxetine (n=7). Each sequence consisted of two 2-week phases. Plasma concentrations of aripiprazole and dehydroaripiprazole were measured using liquid chromatography with mass spectrometric detection. RESULTS Plasma concentrations of aripiprazole and the sum of aripiprazole and dehydroaripiprazole during paroxetine coadministration were 1.7-fold (95% confidence intervals [CI], 1.3-2.1, p<0.001) and 1.5-fold (95% CI 1.2-1.9, p<0.01) higher than those values before the coadministration. These values were not influenced by escitalopram coadministration (1.3-fold, 95% CI 1.1-1.5 and 1.3-fold, 95% CI 1.0-1.5). Plasma dehydroaripiprazole concentrations remained constant during the study. CONCLUSION The present study suggests that low doses of escitalopram can be safely coadministered with aripiprazole, at least from a pharmacokinetic point of view.
Collapse
Affiliation(s)
- K Nemoto
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - K Mihara
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - A Nakamura
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - G Nagai
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - S Kagawa
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - T Suzuki
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - T Kondo
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| |
Collapse
|
39
|
Sharma N, Fahr J, Renaux B, Saifeddine M, Kumar R, Nishikawa S, Mihara K, Ramachandran R, Hollenberg MD, Rancourt DE. Implantation serine proteinase 2 is a monomeric enzyme with mixed serine proteolytic activity and can silence signalling via proteinase activated receptors. Biochem Cell Biol 2013; 91:487-97. [DOI: 10.1139/bcb-2013-0006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Implantation serine proteinase 2 (ISP2), a S1 family serine proteinase, is known for its role in the critical processes of embryo hatching and implantation in the mouse uterus. Native implantation serine proteinases (ISPs) are co-expressed and co-exist as heterodimers in uterine and blastocyst tissues. The ISP1–ISP2 enzyme complex shows trypsin-like substrate specificity. In contrast, we found that ISP2, isolated as a 34 kDa monomer from a Pichia pastoris expression system, exhibited a mixed serine proteolytic substrate specificity, as determined by a phage display peptide cleavage approach and verified by the in vitro cleavage of synthetic peptides. Based upon the peptide sequence substrate selectivity, a database search identified many potential ISP2 targets of physiological relevance, including the proteinase activated receptor 2 (PAR2). The in vitro cleavage studies with PAR2-derived peptides confirmed the mixed substrate specificity of ISP2. Treatment of cell lines expressing proteinase-activated receptors (PARs) 1, 2, and 4 with ISP2 prevented receptor activation by either thrombin (PARs 1 and 4) or trypsin (PAR2). The disarming and silencing of PARs by ISP2 may play a role in successful embryo implantation.
Collapse
Affiliation(s)
- Navneet Sharma
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Jochen Fahr
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Bernard Renaux
- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Mahmoud Saifeddine
- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Rajeev Kumar
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Sandra Nishikawa
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Koichiro Mihara
- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Rithwik Ramachandran
- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Morley D. Hollenberg
- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Derrick E. Rancourt
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| |
Collapse
|
40
|
Mihara K, Sugiura T, Okamura Y, Kanemoto H, Mizuno T, Moriguchi M, Aramaki T, Uesaka K. A predictive factor of insufficient liver regeneration after preoperative portal vein embolization. ACTA ACUST UNITED AC 2013; 51:118-28. [PMID: 24247292 DOI: 10.1159/000356368] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2013] [Accepted: 10/14/2013] [Indexed: 01/10/2023]
Abstract
BACKGROUND Preoperative portal vein embolization (PVE) is performed to enhance the future remnant liver function (FRLF) and volume (FRLV). However, the volume of the nonembolized liver does not increase enough in some patients, which results in an insufficient FRLF. The aim of this study was to evaluate the predictors of insufficient FRLF after PVE for extended hepatectomy. METHODS This retrospective study included 172 patients (107 patients with cholangiocarcinoma, 40 patients with metastatic liver cancer and 25 patients with hepatocellular carcinoma) who underwent PVE before extended hepatectomy. The total liver function was evaluated by measuring the indocyanine green plasma clearance rate (KICG). Computed tomography volumetry was conducted to evaluate the total liver volume and FRLV. The KICG of the future remnant liver (remK) was calculated using the following formula: KICG × FRLV/total liver volume. The safety margin for hepatectomy was set at remK after PVE (post-PVE remK) ≥ 0.05. RESULTS One hundred and twenty-three patients with a post-PVE remK level of >0.05 underwent hepatectomy without postoperative liver failure [sufficient liver regeneration (SLR) group], and 9 patients with a post-PVE remK level of <0.05 did not due to insufficient FRLF [insufficient liver regeneration (ILR) group]. In the SLR group, the KICG values did not change after PVE (median, 0.144-0.146, p = 0.523); however, the %FRLV and remK increased significantly (35.0-44.3%, p < 0.001 and 0.0488-0.0610, p < 0001, respectively). In contrast, in the ILR group, the KICG values decreased significantly (0.128-0.108, p = 0.021) and the %FRLV increased marginally (27.4-32.6%, p = 0.051). As a result, the remK did not increase significantly (0.0351-0.0365, p = 0.213). A receiver operating characteristic curve demonstrated an remK value of 0.04 obtained before PVE (pre-PVE remK) to be the optimal cutoff point for defective liver regeneration. The univariate and multivariate analyses revealed that a pre-PVE remK value of <0.04 was a factor for ILR. It was also correlated with postoperative liver failure in the analysis of the patients who underwent hepatectomy. CONCLUSIONS The patients in the ILR group did not achieve SLR after PVE due to a significant decrease in the KICG and an insufficient increase in %FRLV. A pre-PVE remK value of <0.04 is a useful predictor of insufficient regeneration of the nonembolized liver, even after PVE.
Collapse
Affiliation(s)
- K Mihara
- Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Mihara K, Ramachandran R, Renaux B, Saifeddine M, Hollenberg MD. Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). J Biol Chem 2013; 288:32979-90. [PMID: 24052258 DOI: 10.1074/jbc.m113.483123] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Neutrophil proteinases released at sites of inflammation can affect tissue function by either activating or disarming signal transduction mediated by proteinase-activated receptors (PARs). Because PAR1 is expressed at sites where abundant neutrophil infiltration occurs, we hypothesized that neutrophil-derived enzymes might also regulate PAR1 signaling. We report here that both neutrophil elastase and proteinase-3 cleave the human PAR1 N terminus at sites distinct from the thrombin cleavage site. This cleavage results in a disarming of thrombin-activated calcium signaling through PAR1. However, the distinct non-canonical tethered ligands unmasked by neutrophil elastase and proteinase-3, as well as synthetic peptides with sequences derived from these novel exposed tethered ligands, selectively stimulated PAR1-mediated mitogen-activated protein kinase activation. This signaling was blocked by pertussis toxin, implicating a Gαi-triggered signal pathway. We conclude that neutrophil proteinases trigger biased PAR1 signaling and we describe a novel set of tethered ligands that are distinct from the classical tethered ligand revealed by thrombin. We further demonstrate the function of this biased signaling in regulating endothelial cell barrier integrity.
Collapse
Affiliation(s)
- Koichiro Mihara
- From the Inflammation Research Network, Snyder Institute for Chronic Diseases, and
| | | | | | | | | |
Collapse
|
42
|
Polley D, Mihara K, Ramachandran R, Vliagoftis H, Boitano S, Hollenberg MD, Daines M. Cockroach Allergen Proteinases Regulate Proteinase‐Activated Receptor‐1 (PAR1) Signalling. FASEB J 2013. [DOI: 10.1096/fasebj.27.1_supplement.1171.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Danny Polley
- Physiology & PharmacologyUniversity of CalgaryCalgaryABCanada
| | - Koichiro Mihara
- Physiology & PharmacologyUniversity of CalgaryCalgaryABCanada
| | | | - Harissios Vliagoftis
- Pulmonary Research Group, Department of MedicineUniversity of AlbertaEdmontonABCanada
| | | | | | | |
Collapse
|
43
|
Hollenberg MD, Polley D, Ramachandran R, Mihara K. Biased signaling by proteinase‐activated receptor 1 (PAR1) via activation with neutrophil and cockroach serine proteinases: tracking of distinct receptor dynamics with dual fluorochrome tagged receptors. FASEB J 2013. [DOI: 10.1096/fasebj.27.1_supplement.1171.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Morley D. Hollenberg
- Physiology & PharmacologyUniversity of Calgary Faculty of MedicineCalgaryABCanada
| | - Danny Polley
- Physiology & PharmacologyUniversity of Calgary Faculty of MedicineCalgaryABCanada
| | - Rithwik Ramachandran
- Physiology & PharmacologyUniversity of Calgary Faculty of MedicineCalgaryABCanada
| | - Koichiro Mihara
- Physiology & PharmacologyUniversity of Calgary Faculty of MedicineCalgaryABCanada
| |
Collapse
|
44
|
Ramachandran R, Eissa A, Mihara K, Oikonomopoulou K, Saifeddine M, Renaux B, Diamandis E, Hollenberg MD. Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14. Biol Chem 2012; 393:421-7. [PMID: 22505524 DOI: 10.1515/hsz-2011-0251] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2011] [Accepted: 02/04/2012] [Indexed: 12/15/2022]
Abstract
We compared signalling pathways such as calcium transients, MAPK activation, β-arrestin interactions and receptor internalization triggered by kallikrein-related peptidases (KLKs) 8 and 14 in human and rat proteinase-activated receptor (PAR)2-expressing human embryonic kidney (HEK) and Kirsten transformed rat kidney (KNRK) cells. Further, we analysed processing by KLK8 vs. KLK14 of synthetic human and rat PAR2-derived sequences representing the cleavage-activation domain of PAR2. Our data show that like KLK14, KLK8 can unmask a PAR2 receptor-activating sequence from a peptide precursor. However, whilst KLK8, like KLK14, can signal in rat-PAR2-expressing KNRK cells, this enzyme cannot signal via human PAR2 in HEK or KNRK cells, but rather, disarms HEK PAR1. Thus, KLK8 and KLK14 can signal differentially via the PARs to affect tissue function.
Collapse
Affiliation(s)
- Rithwik Ramachandran
- Department of Physiology and Pharmacology, University of Calgary, Faculty of Medicine, AB, Canada
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Mihara K, Elliott G, Boots A, Nelissen R. Inhibition of p38 kinase suppresses the development of psoriasis-like lesions in a human skin transplant model of psoriasis. Br J Dermatol 2012; 167:455-7. [DOI: 10.1111/j.1365-2133.2012.10939.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Polley D, Mihara K, Saifeddine M, Renaux B, Vliagoftis H, Boitano S, Daines M, Hollenberg MD. Allergen‐derived proteinases: Isolation, characterization and signaling via proteinase‐activated receptors (PARs). FASEB J 2012. [DOI: 10.1096/fasebj.26.1_supplement.664.10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Danny Polley
- Physiology & PharmacologyUniversity of CalgaryCalgaryABCanada
| | - Koichiro Mihara
- Physiology & PharmacologyUniversity of CalgaryCalgaryABCanada
| | | | - Bernard Renaux
- Physiology & PharmacologyUniversity of CalgaryCalgaryABCanada
| | - Harrisios Vliagoftis
- Pulmonary Research GroupDepartment of MedicineUniversity of AlbertaEdmontonABCanada
| | | | | | | |
Collapse
|
47
|
Li Y, Mihara K, Saifeddine M, Krawetz A, Lau DCW, Li H, Ding H, Triggle CR, Hollenberg MD. Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms. Br J Pharmacol 2012; 164:1990-2002. [PMID: 21615723 DOI: 10.1111/j.1476-5381.2011.01501.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND AND PURPOSE We hypothesized that proteinase-activated receptor-2 (PAR2)-mediated vasorelaxation in murine aorta tissue can be due in part to the release of adipocyte-derived relaxing factors (ADRFs). EXPERIMENTAL APPROACH Aortic rings from obese TallyHo and C57Bl6 intact or PAR2-null mice either without or with perivascular adipose tissue (PVAT) were contracted with phenylephrine and relaxation responses to PAR2-selective activating peptides (PAR2-APs: SLIGRL-NH(2) and 2-furoyl-LIGRLO-NH(2) ), trypsin and to PAR2-inactive peptides (LRGILS-NH(2) , 2-furoyl-OLRGIL-NH(2) and LSIGRL-NH(2) ) were measured. Relaxation was monitored in the absence or presence of inhibitors that either alone or in combination were previously shown to inhibit ADRF-mediated responses: L-NAME (NOS), indomethacin (COX), ODQ (guanylate cyclase), catalase (H(2) O(2) ) and the K(+) channel-targeted reagents, apamin, charybdotoxin, 4-aminopyridine and glibenclamide. KEY RESULTS Endothelium-intact PVAT-free preparations did not respond to PAR2-inactive peptides (LRGILS-NH(2) , LSIGRL-NH(2) , 2-furoyl-OLRGIL-NH(2) ), whereas active PAR2-APs (SLIGRL-NH(2) ; 2-furoyl-LIGRLO-NH(2) ) caused an L-NAME-inhibited relaxation. However, in PVAT-containing preparations treated with L-NAME/ODQ/indomethacin together, both PAR2-APs and trypsin caused relaxant responses in PAR2-intact, but not PAR2-null-derived tissues. The PAR2-induced PVAT-dependent relaxation (SLIGRL-NH(2) ) persisted in the presence of apamin plus charybdotoxin, 4-aminopyridine and glibenclamide, but was blocked by catalase, implicating a role for H(2) O(2) . Surprisingly, the PAR2-inactive peptides, LRGILS-NH(2) and 2-furoyl-OLRGIL-NH(2) (but not LSIGRL-NH(2) ), caused relaxation in PVAT-containing preparations from both PAR2-null and PAR2-intact (C57Bl, TallyHo) mice. The LRGILS-NH(2) -induced relaxation was distinct from the PAR2 response, being blocked by 4-aminopyridine, but not catalase. CONCLUSIONS Distinct ADRFs that may modulate vascular tone in pathophysiological settings can be released from murine PVAT by both PAR2-dependent and PAR2-independent mechanisms.
Collapse
Affiliation(s)
- Y Li
- Libin Cardiovascular Institute of Alberta, University of Calgary Faculty of Medicine, Calgary, AB, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, Takei Y, Asaoku H, Takihara Y, Kimura A. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia 2011; 26:365-7. [PMID: 21836610 DOI: 10.1038/leu.2011.205] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
49
|
Ramachandran R, Mihara K, Chung H, Renaux B, Lau CS, Muruve DA, DeFea KA, Bouvier M, Hollenberg MD. Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J Biol Chem 2011; 286:24638-48. [PMID: 21576245 DOI: 10.1074/jbc.m110.201988] [Citation(s) in RCA: 118] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Human neutrophil proteinases (elastase, proteinase-3, and cathepsin-G) are released at sites of acute inflammation. We hypothesized that these inflammation-associated proteinases can affect cell signaling by targeting proteinase-activated receptor-2 (PAR(2)). The PAR family of G protein-coupled receptors is triggered by a unique mechanism involving the proteolytic unmasking of an N-terminal self-activating tethered ligand (TL). Proteinases can either activate PAR signaling by unmasking the TL sequence or disarm the receptor for subsequent enzyme activation by cleaving downstream from the TL sequence. We found that none of neutrophil elastase, cathepsin-G, and proteinase-3 can activate G(q)-coupled PAR(2) calcium signaling; but all of these proteinases can disarm PAR(2), releasing the N-terminal TL sequence, thereby preventing G(q)-coupled PAR(2) signaling by trypsin. Interestingly, elastase (but neither cathepsin-G nor proteinase-3) causes a TL-independent PAR(2)-mediated activation of MAPK that, unlike the canonical trypsin activation, does not involve either receptor internalization or recruitment of β-arrestin. Cleavage of synthetic peptides derived from the extracellular N terminus of PAR(2), downstream of the TL sequence, demonstrated distinct proteolytic sites for all three neutrophil-derived enzymes. We conclude that in inflammation, neutrophil proteinases can modulate PAR(2) signaling by preventing/disarming the G(q)/calcium signal pathway and, via elastase, can selectively activate the p44/42 MAPK pathway. Our data illustrate a new mode of PAR regulation that involves biased PAR(2) signaling by neutrophil elastase and a disarming/silencing effect of cathepsin-G and proteinase-3.
Collapse
Affiliation(s)
- Rithwik Ramachandran
- Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Arizmendi NG, Abel M, Mihara K, Davidson C, Polley D, Nadeem A, El Mays T, Gilmore BF, Walker B, Gordon JR, Hollenberg MD, Vliagoftis H. Mucosal allergic sensitization to cockroach allergens is dependent on proteinase activity and proteinase-activated receptor-2 activation. J Immunol 2011; 186:3164-72. [PMID: 21270400 DOI: 10.4049/jimmunol.0903812] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We have shown that proteinase-activated receptor-2 (PAR(2)) activation in the airways leads to allergic sensitization to concomitantly inhaled Ags, thus implicating PAR(2) in the pathogenesis of asthma. Many aeroallergens with proteinase activity activate PAR(2). To study the role of PAR(2) in allergic sensitization to aeroallergens, we developed a murine model of mucosal sensitization to cockroach proteins. We hypothesized that PAR(2) activation in the airways by natural allergens with serine proteinase activity plays an important role in allergic sensitization. Cockroach extract (CE) was administered to BALB/c mice intranasally on five consecutive days (sensitization phase) and a week later for four more days (challenge phase). Airway hyperresponsiveness (AHR) and allergic airway inflammation were assessed after the last challenge. To study the role of PAR(2), mice were exposed intranasally to a receptor-blocking anti-PAR(2) Ab before each administration of CE during the sensitization phase. Mucosal exposure to CE induced eosinophilic airway inflammation, AHR, and cockroach-specific IgG1. Heat-inactivated or soybean trypsin inhibitor-treated CE failed to induce these effects, indicating that proteinase activity plays an important role. The use of an anti-PAR(2) blocking Ab during the sensitization phase completely inhibited airway inflammation and also decreased AHR and the production of cockroach-specific IgG1. PAR(2) activation by CE acts as an adjuvant for allergic sensitization even in the absence of functional TLR4. We conclude that CE induces PAR(2)-dependent allergic airway sensitization in a mouse model of allergic airway inflammation. PAR(2) activation may be a general mechanism used by aeroallergens to induce allergic sensitization.
Collapse
Affiliation(s)
- Narcy G Arizmendi
- Pulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|